For UK consumer health journalists
• Fingolimod significantly reduced annualised relapse rates by 54-60% vs placebo and disability progression by 30-32% in two-year FREEDOMS study1
• Results build on Phase III TRANSFORMS one-year study showing fingolimod reduced relapses significantly more than interferon beta-1a, a standard of care1,2
• Phase III efficacy and safety data confirm positive benefit-risk profile for lower 0.5 mg dose of fingolimod 1and support planned EU submissions at the end of 2009
Resources to support this story (UK spokespeople interviews, mode of action photos and video, fingolimod fact sheet and patient video) are available. For media enquiries, contact Aurora Healthcare Communications on 020 7424 7940.
Frimley, 30th September, 2009 – Novartis Pharmaceuticals UK Ltd. announced today that initial results from the Phase III FREEDOMS study confirmed the two-year efficacy of FTY720...